ArticleAmerican journal of cancer research2022

Interfering with ITGB1-DT expression delays cancer progression and promotes cell sensitivity of NSCLC to cisplatin by inhibiting the MAPK/ERK pathway.

Dan Li et al.PubMed ↗Full text ↗

No numbers read from the abstract.